glp 1 coverage GLP-1 in Employer Plans Could Nearly Double in 2024 Which Weight Loss Meds Are

8,9,30 The agents used in these trials, including higher-dose semaglutide (2.4 mg) and the dual GLP-1/GIP receptor agonist tirzepatide, have demonstrated compelling benefits

While previous generations GLP-1 agonists (liraglutide) have led to weight loss of 5-10% in most cases, semaglutide can lead to weight loss of up to 20%

Despite ongoing safety concerns and investigations, Victoza remains available on the market and continues to be prescribed for type 2 diabetes

Likewise, GLP-1s have shown other wide-reaching benefits, such as improving cholesterol and blood pressure levels, and reducing the risk of stroke

Medical necessity The medication must be medically necessary for the treatment to be eligible for the Novo Nordisk PAP